Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome

PHASE2TerminatedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Irritable Bowel Syndrome
Interventions
DRUG

Lubiprostone

8 mcg administered orally twice daily (BID)

DRUG

Placebo

Matching placebo, 0 mcg administered orally twice daily (BID)

Trial Locations (16)

21742

Meritus Center for Clinical Research, Hagerstown

27612

Wake Research Associates, LLC, Raleigh

28025

PMG Research of Charlotte, Concord

28210

PMG Research of Charlotte, Charlotte

28304

Cumberland Research Associates, LLC, Fayetteville

33133

Prestige Clinical Research Center, Miami

34684

Advanced Gastroenterology Associates, LLC, Palm Harbor

35801

E Squared Research, Inc., Huntsville

38305

Clinical Research Solutions, Jackson

55905

Mayo Clinic, Rochester

72117

Arkansas Gastroenterology, North Little Rock

75071

Wellness Clinical Research Associates, McKinney

75093

Advanced Clinical Research Associates, Plano

77079

Houston Endoscopy Research Center, Houston

91910

GW Research Inc., Chula Vista

92377

Inland Empire Liver Foundation, Rialto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Takeda

INDUSTRY

collaborator

Sucampo AG

INDUSTRY

lead

Sucampo Pharma Americas, LLC

INDUSTRY